The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of PD-L1 expression on survival in patients with unresectable/recurrent gastric cancer receiving first-line chemotherapy without immune checkpoint inhibitors.
 
Hidekazu Hirano
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Fujifilm; Novartis; Taiho Pharmaceutical; Teijin Pharma
Research Funding - BeiGene (Inst)
 
Yasuhide Yamada
Honoraria - Taiho Pharmaceutical
 
Kengo Nagashima
Consulting or Advisory Role - Kowa; Senju Pharmaceutical; Toray Industries
 
Nobuyoshi Hiraoka
No Relationships to Disclose
 
Shigeki Sekine
Honoraria - MSD (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst)
 
Naoki Takahashi
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Mizutomo Azuma
No Relationships to Disclose
 
Satoru Iwasa
Employment - Chugai Pharma
Honoraria - Agilent; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
 
Keisuke Kanato
No Relationships to Disclose
 
Nozomu Machida
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck KGaA; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - ALX Oncology (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takahiro Kinoshita
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo; Gunze; Intuitive Surgical; Johnson & Johnson; Kaken Pharmaceutical; Medtronic; MSD; Olympus Medical Systems; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; TERUMO; Tsumura & Co.
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan; Daiichi Sankyo; Johnson & Johnson K.K; Medtronic; Olympus Medical Systems; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Tsumura & Co.
 
Hiroaki Hata
No Relationships to Disclose
 
Hisato Kawakami
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo Co. Ltd.,; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kobayashi Pharmaceutical (Inst)
 
Daisuke Takahari
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo/UCB Japan; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Toshiyasu Ojima
No Relationships to Disclose
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Merck KGaA; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst)
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Daiichi-Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Takeda (Inst)
 
Yukinori Kurokawa
Honoraria - Daiichi Sankyo; Johnson & Johnson; Kaken Pharmaceutical; Lilly; MC Medical; Medtronic; Nippon Kayaku; Ono Pharmaceutical; Stryker; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Masanori Terashima
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Intuitive Surgical; Johnson & Johnson; Lilly; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Takaki Yoshikawa
Honoraria - Astellas Pharma; AstraZeneca; BMS; Chugai Pharma; Daiichi Sankyo; EA Pharma; Intuitive Surgical; Japan Blood Products Organization; Johnson & Johnson/Janssen; Lilly; Medtronic; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - MSD Oncology; TERUMO
Research Funding - Lilly